GLP-1 Medicines, Perimenopause and Menopause: What Is Known So Far?

Perimenopause and menopause can bring changes in where weight sits, sleep, mood, body composition and metabolic health, sometimes all at once. It's no surprise that many people start asking about GLP-1 medicines in midlife. The key thing to know up front: GLP-1 medicines treat specific conditions like type 2 diabetes and obesity. They don't treat menopause itself, and the research specifically about menopause is still early.

Why midlife can feel different

Hormonal shifts can affect sleep, hot flashes, mood and how body composition changes. But age, activity, stress, other health conditions, medicines and life circumstances all play a part too. Weight gain or lower energy in midlife isn't automatically "just menopause," and it isn't a personal failure.

What GLP-1 treatment has evidence for

In the US, GLP-1 and related medicines are approved for specific uses, such as type 2 diabetes and chronic weight management in eligible adults, with some products also approved to reduce heart risk or for other conditions. Those approvals came from trials designed around those goals. They don't establish that these medicines treat hot flashes, sleep disruption, bone health or other menopausal symptoms.

If you're considering a GLP-1 medicine for weight management, you should meet the criteria on the relevant label and have a proper conversation about benefits and risks.

What the menopause-specific research shows so far

A 2026 scoping review in Cureus gathered what's been published on GLP-1 medicines in menopausal and postmenopausal women. Some takeaways:

• GLP-1 medicines were associated with weight loss and reduced waist size in this group, and semaglutide and liraglutide appeared to work similarly in pre- and postmenopausal women.
• Evidence on hot flashes is preliminary. Any benefit may be partly due to weight loss.
• Early studies have looked at combining GLP-1 medicines with menopausal hormone therapy. A retrospective study and a preliminary conference report suggested possible added benefits, but these designs can't prove cause and effect.
• The authors highlighted major limits: many findings come from animal studies, human studies are often small or retrospective, most lasted only three to six months, and menopausal women are underrepresented in trials.

Large obesity trials do include many midlife women, which helps. But that's not the same as a trial designed to answer menopause-specific questions. Claims that a GLP-1 "balances hormones" or fixes all menopause-related weight change go beyond the evidence.

Muscle and bone are worth a mention

Midlife is already a time when muscle and bone health need attention, and any significant weight loss can include some loss of muscle. That's one reason to ask about protein and strength training as part of the plan (see why strength training can matter on GLP-1 treatment).

What to discuss with a clinician

Describe the symptoms that bother you most, whether that's weight change, sleep, hot flashes, mood, blood sugar, joint pain or something else. Then ask:

• Which evidence-based treatments address each of these?
• Is a GLP-1 medicine appropriate for my health profile?
• Does anything else need checking, such as thyroid function or sleep apnea?

If you use hormone therapy or other medicines, keep any changes to them with the prescriber who manages them, rather than adjusting based on a weight-loss claim. If you use a birth control pill during perimenopause, ask about tirzepatide specifically, because its US labels advise a backup or non-oral method for 4 weeks after starting and after each dose increase.

Midlife health is about more than one number on the scale. A thoughtful plan can address menopause symptoms, metabolic health and weight goals as related but separate parts of your wellbeing.